Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Additional Information) (Details)

v3.23.3
Discontinued Operations (Additional Information) (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 10, 2015
USD ($)
Feb. 29, 2020
USD ($)
Milestonepayment
Sep. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Loss on impairment of property and equipment     $ 0   $ 3,663     $ 485 $ 3,662  
Impairment loss     0   17,746       17,746 $ 19,681
Change in contingent consideration valuation     0   1,222     (19,900) $ (1,254)  
Assets of discontinued operation     0         0   1,480
Liabilities of discontinued operation     $ 0         $ 0   20,995
Intangible asset, useful life     10 years         10 years    
Alkermes | Contingent Consideration, Fourth Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Minimum Royalty Percenatge     10.00%         10.00%    
Maximum Royalty Percenatge     12.00%         12.00%    
Transfer Agreement [Member]                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Loss on impairment of property and equipment                   $ 485
Change in contingent consideration valuation       $ 19,900            
Recro Pharma Incorporation [Member] | Alkermes                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones $ 60,000                  
Collaborative arrangements, milestone payments period 7 years                  
Recro Pharma Incorporation [Member] | Purchase and Sale Agreement | Alkermes                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones $ 140,000                  
Amendment To Purchase And Sale Agreement [Member] | Recro Pharma Incorporation [Member] | Alkermes | Contingent Consideration, First Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Business acquisition contingent consideration, first milestone payment             $ 5,000      
Business acquisition contingent consideration possible milestone payments           $ 5,000        
Amendment To Purchase And Sale Agreement [Member] | Recro Pharma Incorporation [Member] | Alkermes | Contingent Consideration, Second Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Business Acquisition Contingent Consideration Second Milestone Payments         $ 1,200          
Amendment To Purchase And Sale Agreement [Member] | Recro Pharma Incorporation [Member] | Alkermes | Contingent Consideration, Fourth Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Maximum royalty payment percentage               30.00%    
Amendment To Purchase And Sale Agreement [Member] | Recro Pharma Incorporation [Member] | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval [Member] | Alkermes | Contingent Consideration, Second Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Business acquisition, contingent consideration, equal annual milestone payments   $ 6,400                
Business acquisition contingent consideration possible milestone payments   $ 45,000                
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment   7                
Amendment To Purchase And Sale Agreement [Member] | Recro Pharma Incorporation [Member] | Milestone Payments Due Following Regulatory Approval [Member] | Alkermes | Contingent Consideration, Second Component                    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                    
Business acquisition contingent consideration possible milestone payments   $ 5,000